As of June 15, 2025, GT Biopharma Inc (GTBP) reports a Net Margin of -79485.19%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of GT Biopharma Inc's Net Margin
Over recent years, GT Biopharma Inc's Net Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -79485.19% |
| 2023-12-31 | -79485.19% |
This trend highlights how GT Biopharma Inc manages its overall profitability and cost control over time.
Comparing GT Biopharma Inc's Net Margin to Peers
To better understand GT Biopharma Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| GT Biopharma Inc (GTBP) | -79485.19% |
| Liminal BioSciences Inc (LMNL) | 124.69% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, GT Biopharma Inc's Net Margin is lower than all peers, which may indicate challenges in controlling expenses or competitive pricing pressures.